These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 733940)

  • 41. [Histopathological study regarding the protective effect of elastase on cis-platinum-induced renal toxicity].
    Suzuki M; Ohwada M; Sekiguchi I; Tamada T
    Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):941-7. PubMed ID: 2778382
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of cis-diamminedichloroplatinum (II)--induced renal toxicity in the rat.
    Jones MM; Basinger MA; Mitchell WM; Bradley CA
    Cancer Chemother Pharmacol; 1986; 17(1):38-42. PubMed ID: 3698175
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduction of cis-dichlorodiammineplatinum(II) caused nephrotoxicity by indazolone carboxylic acid.
    Radacić M; Boranić M; Skarić D; Skarić V; Mihalić H; Gajsak V; Jercić J; Lelieveld P
    Oncology; 1987; 44(1):34-7. PubMed ID: 3561926
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Control of some aspects of cis-platinum nephrotoxicity.
    Jones MM; Basinger MA; Craft WD; Domingo JL; Llobet JM
    Arch Toxicol; 1986 Oct; 59(3):167-71. PubMed ID: 3028320
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Renal toxicity studies of protein-bound platinum(cis).
    Cole WC; Wolf W
    Chem Biol Interact; 1981 Jun; 35(3):341-8. PubMed ID: 7194744
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nephrotoxicity of cis-platin comparing young and adult rats.
    Jongejan HT; Provoost AP; Wolff ED; Molenaar JC
    Pediatr Res; 1986 Jan; 20(1):9-14. PubMed ID: 3945520
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effective prevention of the nephrotoxicity of cis-platin (CDDP) by administration of sodium 2-mercaptoethane-sulfonate (MESNA) in rats.
    Kempf SR; Ivankovic S; Wiessler M; Schmähl D
    Br J Cancer; 1985 Dec; 52(6):937-9. PubMed ID: 3935152
    [No Abstract]   [Full Text] [Related]  

  • 48. Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model.
    Borch RF; Pleasants ME
    Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6611-4. PubMed ID: 230514
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cisplatin nephrotoxicity: a summary of preventative interventions.
    Finley RS; Fortner CL; Grove WR
    Drug Intell Clin Pharm; 1985 May; 19(5):362-7. PubMed ID: 3891281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nephrotoxicity of cis-diamminedichloroplatinum (II) (cis-platinum) and the additive effect of antibiotics: morphological and functional observation in rats.
    Kawamura J; Soeda A; Yoshida O
    Toxicol Appl Pharmacol; 1981 May; 58(3):475-82. PubMed ID: 7195614
    [No Abstract]   [Full Text] [Related]  

  • 51. Orgotein (superoxide dismutase): a drug for the amelioration of radiation-induced side effects. A double-blind, placebo-controlled study in patients with bladder tumours.
    Menander-Huber KB; Edsmyr F; Huber W
    Urol Res; 1978; 6(4):255-7. PubMed ID: 105443
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of superoxide dismutase on glomerular nephritis.
    Adachi T; Fukuta M; Ito Y; Hirano K; Sugiura M; Sugiura K
    Biochem Pharmacol; 1986 Jan; 35(2):341-5. PubMed ID: 3002390
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Precocene II nephrotoxicity in the rat.
    Schrankel KR; Grossman SJ; Hsia MT
    Toxicol Lett; 1982 Jul; 12(2-3):95-100. PubMed ID: 7112615
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Platinum drugs: combined anti-lymphoproliferative and nephrotoxicity assay in rats.
    Aggarwal SK; Broomhead JA; Fairlie DP; Whitehouse MW
    Cancer Chemother Pharmacol; 1980; 4(4):249-58. PubMed ID: 7438327
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Additional pharmacological aspects of orgotein, a metalloprotein with superoxide-dismutase activity.
    Borrelli F; Serafini C; Mattalia G; Caprino L
    Arzneimittelforschung; 1979; 29(5):781-5. PubMed ID: 159058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Platinum nephrotoxicity.
    Hardaker WT; Stone RA; McCoy R
    Cancer; 1974 Oct; 34(4):1030-32. PubMed ID: 4421400
    [No Abstract]   [Full Text] [Related]  

  • 57. The Investigation of the Antitumor Agent Toxicity and Capsaicin Effect on the Electron Transport Chain Enzymes, Catalase Activities and Lipid Peroxidation Levels in Lung, Heart and Brain Tissues of Rats.
    Kursunluoglu G; Taskiran D; Kayali HA
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30544766
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease.
    Mapuskar KA; Wen H; Holanda DG; Rastogi P; Steinbach E; Han R; Coleman MC; Attanasio M; Riley DP; Spitz DR; Allen BG; Zepeda-Orozco D
    Redox Biol; 2019 Jan; 20():98-106. PubMed ID: 30296702
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention.
    Schacht J; Talaska AE; Rybak LP
    Anat Rec (Hoboken); 2012 Nov; 295(11):1837-50. PubMed ID: 23045231
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cisplatin nephrotoxicity: molecular mechanisms.
    Hanigan MH; Devarajan P
    Cancer Ther; 2003; 1():47-61. PubMed ID: 18185852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.